2025

Phase I Study: CD39⁺CD103⁺CD8⁺ Selected TIL Therapy (AGX-148) Demonstrates Clinical Activity in Patients with Metastatic Solid Tumors

Colin Thalhofer, Ryan Montler, Elaine Ballinger, Jessica Cross, Nicholas Morris, Jake Moses, Eric Tran, Nelson Sanjuan, Matthew Taylor, Christopher Fountain, Brendan Curti, Andrew Weinberg 

2025

AAI Meeting

 Utilizing CD39 and CD103 to identify tumor-reactive TCRs and transducing them into T cells with no tumor reactivity leads to tumor killing in-vitro 

 Ryan Montler, Colin Thalhofer, Elaine Ballinger, Jessica Cross, Nicholas Morris, Jake Moses, Eric Tran, Nelson Sanjuan, Matthew Taylor, Christopher Fountain, Brendan Curti, Andrew Weinberg2 

2024

Tumor-Reactive Til With An Exhausted Phenotype Can Be Expanded And Regress Human Tumors

AACR Annual Meeting

Colin J. Thalhofer, Ryan Montler, Elaine Ballinger, Jessica Cross, Nicholas Morris, Nelson Sanjuan, Matthew Taylor, Christopher Fountain, Roxanne Payne, James Cardia, Brendan Curti, Andrew D. Weinberg

2020

Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYLTM

SITC | Virtual Conference

Colin J. Thalhofer, Ryan Montler, Melissa Maxwell, Dingxue Yan, James Cardia, Simon P. Fricker, Nicholas Morris, Jacob Moses, Joshua F. Rios, Tarsem Moudgil, Bernard A. Fox, Richard B. Bell, Andrew D. Weinberg

2018

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

Thomas Duhen, Rebekka Duhen, Ryan Montler, Jake Moses, Tarsem Moudgil, Noel F. de Miranda, Cheri P. Goodall, Tiffany C. Blair, Bernard A. Fox, Jason E. McDermott, Shu-Ching Chang, Gary Grunkemeier, Rom Leidner, Richard Bryan Bell, & Andrew D. Weinberg